Department of Medicine, Infectious Diseases Section, VA Pittsburgh Healthcare System, Pittsburgh, PA; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
Department of Medicine, Infectious Diseases Section, VA Pittsburgh Healthcare System, Pittsburgh, PA; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
Am J Infect Control. 2021 Oct;49(10):1237-1241. doi: 10.1016/j.ajic.2021.07.019. Epub 2021 Aug 5.
Coronavirus disease 2019 (COVID-19) outbreaks often occur in nursing homes and prompt frequent surveillance testing for SARS-CoV-2. A single dose of the BNT162b2 vaccine reduces viral load and transmission. In this study, we describe the real-world efficacy of BNT162b2 single-dose vaccination during a COVID-19 outbreak at a Veterans Affairs Community Living Center (CLC).
From 12/2/20 to 5/14/21, twice weekly antigen testing was used to detect COVID-19 among 146 residents at the CLC. Residents without a prior history of COVID-19 who agreed to immunization were vaccinated with the BNT162b2 vaccine on 12/16/20 and 1/6/21. Single-dose vaccine efficacy was determined for days 1-21 and days 14-21 after the first vaccine dose.
The outbreak occurred from 12/2/20 to 1/7/21 with an attack rate of 30.8% (45/146); 46.7% (21/45) of the cases were due to asymptomatic COVID-19. One unit accounted for 77.8% (35/45) of the cases. In the vaccine analysis, 116 residents were a median age of 74.5 years and 93.1% (108/116) had ≥ 1 comorbid condition. Between the first and second dose, 15.5% (15/97) of vaccinated residents, and 21.2% (4/19) of unvaccinated residents developed COVID-19 (P = .81). One week after the second dose, no cases of COVID-19 occurred.
Albeit limited by the small numbers, a single dose of the BNT162b2 vaccine was not efficacious at preventing COVID-19 during this nursing home outbreak.
2019 年冠状病毒病（COVID-19）疫情常在疗养院暴发，并促使频繁进行 SARS-CoV-2 的监测检测。一剂 BNT162b2 疫苗可降低病毒载量和传播。在这项研究中，我们描述了 BNT162b2 单剂疫苗在退伍军人事务社区生活中心（CLC）COVID-19 疫情期间的真实世界疗效。
从 2020 年 12 月 2 日至 2021 年 5 月 14 日，每周两次使用抗原检测来检测 CLC 中 146 名居民的 COVID-19。没有 COVID-19 既往史且同意接种疫苗的居民于 2020 年 12 月 16 日和 2021 年 1 月 6 日接种 BNT162b2 疫苗。第 1 剂疫苗后第 1-21 天和第 14-21 天确定单剂疫苗的疗效。
疫情于 2020 年 12 月 2 日至 1 月 7 日暴发，发病率为 30.8%（45/146）；46.7%（21/45）的病例为无症状 COVID-19。一个单位占病例的 77.8%（35/45）。在疫苗分析中，116 名居民的中位年龄为 74.5 岁，93.1%（108/116）有≥1 种合并症。在第 1 剂和第 2 剂之间，15.5%（15/97）的接种居民和 21.2%（4/19）的未接种居民发生 COVID-19（P=.81）。第 2 剂后 1 周，未发生 COVID-19 病例。
虽然受到数量限制，但在这次疗养院暴发中，一剂 BNT162b2 疫苗在预防 COVID-19 方面并不有效。
